Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Other Accumulated Expenses (2016 - 2022)

Ovid Therapeutics filings provide 7 years of Other Accumulated Expenses readings, the most recent being $139167.0 for Q1 2022.

  • Quarterly Other Accumulated Expenses fell 79.33% to $139167.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $139167.0 through Mar 2022, down 79.33% year-over-year, with the annual reading at $546464.0 for FY2021, 230.12% up from the prior year.
  • Other Accumulated Expenses hit $139167.0 in Q1 2022 for Ovid Therapeutics, down from $546464.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $2.0 million in Q2 2021 and bottomed at $119940.0 in Q3 2021.
  • Average Other Accumulated Expenses over 5 years is $342914.5, with a median of $184923.0 recorded in 2018.
  • The largest annual shift saw Other Accumulated Expenses skyrocketed 621.03% in 2021 before it tumbled 79.33% in 2022.
  • Ovid Therapeutics' Other Accumulated Expenses stood at $184923.0 in 2018, then increased by 25.51% to $232095.0 in 2019, then fell by 28.68% to $165536.0 in 2020, then skyrocketed by 230.12% to $546464.0 in 2021, then plummeted by 74.53% to $139167.0 in 2022.
  • Per Business Quant, the three most recent readings for OVID's Other Accumulated Expenses are $139167.0 (Q1 2022), $546464.0 (Q4 2021), and $119940.0 (Q3 2021).